Percheron receives $0.70m R&D Tax Incentive Rebate

Aug 30, 2026 at 10:06 PM EDT · Issued by Percheron Therapeutics Limited via ASX

Filed with ASX · Aug 30, 2026 at 10:06 PM EDT

On 6ix: 6ix.com/news/percheron-receives-dollar0.70m-randd-tax-incentive-rebate

Percheron Therapeutics Limited ABN 41 095 060 745 ASX: PER | FSE: AWY | US OTC: ATHJY PERCHERON RECEIVES $0.70 MILLION RESEARCH AND DEVELOPMENT TAX INCENTIVE REBATE Melbourne, Australia – 31 August 2026: Percheron Therapeutics Limited (ASX: PER) (‘the...

View Attachment

6ix hasn’t read this filing yet.

Percheron Therapeutics Limited on 6ix

In the deck

Percheron Therapeutics — Investor Presentation (September 2026)14 slidesSep 1, 2026

Earlier from Percheron Therapeutics

Trading HaltAug 27
Vanderbilt Health to conduct clinical trial of HMBD-002Aug 27
Appendix 4E and Annual ReportAug 19
Appendix 4G and Corporate Governance StatementAug 18
Application for quotation of securities - PERAug 14

Later from Percheron Therapeutics

Notification of cessation of securities - PERAug 31
Change of Director's Interest NoticeAug 31
Transitional appointment of Executive DirectorAug 31
Initial Director's Interest NoticeAug 31
Proposed issue of securities - PERAug 31

All Percheron Therapeutics news releases

Follow Percheron Therapeutics into a list and get an email when it puts out news.

Follow Percheron Therapeutics